AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

Friday, November 15, 2019

ATTEST: AFib ablation slows progression to persistence

By Mitchel Zoler

AFib ablation cut the rate of paroxysmal to persistent arrhythmia progression by 89%, compared with medical management.

You can take the MDedge Podcasts survey by clicking here.

Other stories:

FDA panel rejects new empagliflozin indication for type 1 diabetes

Panelists voted 14-2 against the application and criticized the limited data supporting the application.

ACP recommends ways to address rising drug prices

One of the College’s suggestions is for the Medicare Part D low-income subsidy program to be modified.

Drug spending driving up Part B premiums and deductibles

The standard premium will climb 6.7% in 2020.

Methotrexate affected joint erosions, not pain, in patients with erosive hand OA

The results were observed for 10 mg methotrexate per week at 3 months and 12 months.

You can contact the MDedge Daily Medical News by emailing us at podcasts@mdedge.com or following us on Twitter at @MDedgeTweets.